What are the ASCO recommendations for treatment of stage IV non–small cell lung cancer (NSCLC) in patients with PS 2, non-SCC, and negative or unknown tumor EGFR-sensitizing mutation and ALK or ROS1 gene rearrangement status?

Updated: Jun 05, 2020
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print
Answer

For patients with PS 2, non-SCC, and negative or unknown tumor EGFR-sensitizing mutation and ALK or ROS1 gene rearrangement status, the guidelines recommend combination therapy, single-agent therapy, or palliative therapy alone, selected on the basis of shared decision making.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!